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Foxa1 is essential for development 
and functional integrity of the 
subthalamic nucleus
Emanuel Gasser1, Helge C. Johannssen2, Thomas Rülicke3, Hanns Ulrich Zeilhofer2,4 & 
Markus Stoffel1
Inactivation of transcription factor Foxa1 in mice results in neonatal mortality of unknown cause. 
Here, we report that ablation of Foxa1 causes impaired development and loss of the subthalamic 
nucleus (STN). Functional deficits in the STN have been implicated in the etiology of Huntington’s and 
Parkinson’s disease. We show that neuronal ablation by Synapsin1-Cre-mediated Foxa1 deletion is 
sufficient to induce hyperlocomotion in mice. Transcriptome profiling of STN neurons in conditional 
Foxa1 knockout mice revealed changes in gene expression reminiscent of those in neurodegenerative 
diseases. We identified Ppargc1a, a transcriptional co-activator that is implicated in neurodegeneration, 
as a Foxa1 target. These findings were substantiated by the observation of Foxa1-dependent demise of 
STN neurons in conditional models of Foxa1 mutant mice. Finally, we show that the spontaneous firing 
activity of Foxa1-deficient STN neurons is profoundly impaired. Our data reveal so far elusive roles of 
Foxa1 in the development and maintenance of STN function.
The subthalamic nucleus (STN) is an integral part of the basal ganglia circuitry that is involved in the control of 
movement1,2. Within this circuitry, the STN is best described for its function in the suppression of competing 
motor programs that would otherwise interfere with the execution of the desired movement3,4. Consequently, 
pathological changes that affect the signal propagation through the STN are associated with the manifestation of 
severe motor disorders like Parkinson’s disease (PD), Huntington’s disease (HD) and hemiballism2,5. Moreover, 
in PD patients, high-frequency stimulation or bilateral lesions of the STN can provide a significant improvement 
in cardinal motor symptoms, including bradykinesia, tremor and gait6,7. Within the basal ganglia, the initiation, 
execution and termination of voluntary movement is modulated by the hyperdirect, direct and indirect pathways 
that are conveying cortico-striatal inputs to the main output structures of the basal ganglia, the entopeduncular 
nucleus (EP) and the substantia nigra pars reticulata (SNr)1,4. Both, EP and the SNr, exert a GABAergic inhibitory 
effect on their target brain areas, thereby suppressing movement execution8,9. STN neurons modulate the activity 
of both output nuclei by sending glutamatergic projections to the EP and the SNr and activation (hyperdirect 
pathway) or disinhibition (indirect pathway) of STN neurons results in an increased firing rate of EP and SNr 
neurons and a concomitant reduction of locomotor activity1,2,4. While the significance of the STN in brain circuits 
controlling movement has been subject of extensive research for many decades, considerably less is known about 
the underlying molecular mechanisms for its development and functional preservation.
Foxa1 and Foxa2 (Foxa1/2) are members of the forkhead family of winged-helix transcription factors that 
play important roles in the development and maintenance of multiple organ systems10. Loss-of-function studies 
have established redundancies in the functional repertoire of Foxa1/2, which has been attributed to their perfect 
and extensive sequence homology in the DNA binding domain and transactivation domains, respectively, and 
mostly overlapping expression patterns10. Global ablation of Foxa1 in mice results in early perinatal death in the 
presence of severe metabolic deteriorations, but in the absence of any overt developmental deficits11,12. Additional 
studies have shown that Foxa1/2 redundantly regulate the development and functional maintenance of midbrain 
dopaminergic neurons13–16. Consistent with the role of dopamine in the control of movement, PD-like motor 
impairments have been reported following Foxa1/2 deletion from dopaminergic neurons, as well as in heterozy-
gous Foxa2 knock-out mice16–19. While Foxa2 has been reported to promote spontaneous activity by positively 
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regulating orexin and MCH expression in neurons of the lateral hypothalamus, little is known about the actions 
of central Foxa1 outside the dopaminergic neurons20.
In this study we analyzed the expression of Foxa1 in the brain, using a BAC transgenic Foxa1 reporter mouse 
model. We detected strong Foxa1 expression in the developing and adult STN and studied the consequences of 
Foxa1 ablation on STN development and function. We found that Foxa1 is absolutely required for the formation 
of the STN and that the conditional deletion of Foxa1 from post-mitotic neurons causes a hyperkinetic state in 
animals, accompanied by neurodegeneration and functional deficits in the STN.
Results
Foxa1 is essential for STN development. To characterize the identity and function of Foxa1-expressing 
brain nuclei we generated a BAC transgenic Foxa1eGFP reporter mouse, as well as a conditional Foxa1 knock-out 
mouse (Figs 1A and Fig. S1). Prominent Foxa1eGFP expression was detected in the perikarya of the STN, the 
ventral premammillary nucleus, the supramammillary nuclei, the posterior hypothalamic area and the ventral 
tegmental area (VTA) (Figs S2 and S3A,B). To establish the molecular signature of Foxa1-expressing neurons, 
we isolated neurons from newborn Foxa1eGFP mice and collected the identical numbers of Foxa1eGFP-positive 
and Foxa1eGFP-negative cells by flow cytometry. Transcriptome analysis of these cells and cross-reference with 
the available literature and the in-situ data from the Allen Institute for Brain Science (www.alleninstitute.org) 
revealed a strong enrichment of STN markers in the Foxa1eGFP-positive neuronal population (Table S1).
In light of the involvement of Foxa1/2 in the development of midbrain dopaminergic neurons, we speculated 
that Foxa1 might play a role in STN development. Indeed, we found a significant fraction of STN-enriched tran-
scripts to be depleted from sorted Foxa1eGFP neurons of newborn Foxa1∆/∆ (∆ Foxa1) mice, when compared to 
their Foxa1fl/fl (cFoxa1) littermates (Table S2). The hypothesis of a Foxa1-dependent defect in STN development 
was subsequently corroborated by the finding that STN markers like Pitx2, neurotensin (Nts), C130021l20Rik, 
Figure 1. Absent subthalamic nucleus in newborn ∆Foxa1 mice. (A) Strategy for the generation of the 
Foxa1eGFP BAC transgenic reporter construct. Most parts of Exon2 were replaced by sequences coding for 
eGFP, the polyadenylation sequence (PA) and the Neomycin (NEO) selection cassette. Expression from the 
recombined BAC transgene yields a fusion protein consisting of the N-terminal 31 amino acids of Foxa1 
fused to eGFP. (B) Immunohistochemical and RNA in situ hybridization analysis of STN-enriched proteins 
(Foxp2, Calb2) or transcripts (Pitx2, Nts, C130021I20Rik) on coronal brain sections of newborn ∆ Foxa1 
mice (P0). Arrows indicate the absent STN. Shown are representative images. (C,D) Immunohistochemical 
analysis of (C) Foxa1eGFP or (D) Foxa1eGFP, Hoechst and NeuN on coronal brain sections of newborn ∆ Foxa1 
mice (P0). Arrows indicate the absent STN. Shown are representative images. 3V, third ventricle; PMv, ventral 
premammillary nucleus; STN, subthalamic nucleus. Scale bars represent 100 μm.
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Foxp2 or calretinin (Calb2) were absent from the presumptive STN in newborn ∆ Foxa1 mice (Fig. 1B). This 
was further confirmed by the complete absence of Foxa1eGFP expression and the drastic reduction of cell nuclei 
from the anatomical location of the STN in ∆ Foxa1 newborn mice (Fig. 1C,D), while a significantly increased 
clustering of Foxa1eGFP neurons in the medial zone was observed (Fig. 1C and Fig. S3C,D). Together, these data 
demonstrate the crucial role of Foxa1 for STN development.
Foxa1 deficiency affects early stages of STN formation. The STN phenotype of ∆ Foxa1 mice is 
strikingly reminiscent of the brain developmental defects observed in Pitx2-deficient embryos that are devoid 
of any subthalamic specification21. The same study revealed that in mice, prospective STN neurons exit the cell 
cycle around E10.5 – E12.5, before migrating to their final destination by E14.5. To address a potential interplay 
of Foxa1 and Pitx2 in STN development, the expression of Pitx2 and Foxa1eGFP in the developing hypothala-
mus of ∆ Foxa1 embryos was investigated. At E12.5, Foxa1eGFP expression in ∆ Foxa1 embryos was unaltered 
when compared to cFoxa1 embryo littermates (Fig. 2A). Moreover, neither obvious aberrations in the prolifer-
ation of neural progenitors nor an increase of apoptosis were evident in the developing hypothalamus at E12.5 
or P0 (Fig. S4A–G). In contrast to Pitx2 mRNA, Foxa1eGFP is already expressed in the still dividing progenitor 
cells of the ventricular zone, indicating a more upstream function of Foxa1 in STN development (Fig. 2A and 
Fig. S4A)21,22. Although Pitx2 was still abundantly expressed in the developing hypothalamus of either genotype, 
it was displaced to more lateral regions in ∆ Foxa1 embryos and the proportion of neurons displaying overlap-
ping Foxa1eGFP and Pitx2 expression was markedly reduced, when compared to the total population of Foxa1eGFP 
neurons (Fig. 2A and Fig. S5A–C). Of note, ∆ Foxa1 mice additionally displayed major deviations in the struc-
tural organization of their mammillary region, similar to what has been reported also for the Pitx2 null model 
(Fig. S5D)23. When we analyzed later stages of development, at E14.5, the STN cell population is clearly dis-
cernible in cFoxa1 embryos, where they form a compact cell cluster in lateral positions of the developing hypo-
thalamus, visualized by Foxa1eGFP, Pitx2, Calb2, and Foxp2 expression (Fig. 2B). This is in contrast to ∆ Foxa1 
embryos, where no distinct STN population was detected at E.14.5 (Fig. 2B). Despite the reported wide-ranging 
redundancy of Foxa1/2 in the development of multiple organ systems, Foxa2 apparently cannot substitute for the 
absence of Foxa1 in STN development. Accordingly, we found Foxa2 expression in the E12.5 developing hypo-
thalamus limited to a restricted region, close to the dorsal barrier of the Foxa1eGFP population, with no compen-
satory up-regulation occurring in the ∆ Foxa1 embryos (Fig. S6A). Furthermore, Foxa2 is completely absent from 
the E14.5 and newborn STN, while it overlaps extensively with Foxa1eGFP in the developing midbrain (Fig. 2C). 
Finally, the expression of Lmx1a and Shh, two established Foxa1/2 targets in the developing midbrain, was not 
disrupted in the developing hypothalamus of ∆ Foxa1 embryos at E12.5 (Fig. S6B,C)13,14,24. Taken together, these 
data indicate that Foxa1 is required already at the initial stages of STN development and that similar to the Pitx2 
null model, STN neurons are born in ∆ Foxa1 embryos, but subsequently fail to differentiate and migrate to their 
respective destination to establish the STN21.
Brain-specific ablation of Foxa1 causes hyperlocomotion in adult mice. Because of the heavy 
implication of the STN in etiology and treatment of dyskinesias, we next sought to address the importance of 
Foxa1 in the adult STN in the modulation of motor behavior. To study Foxa1-dependent actions in the mature 
STN in addition to its role in STN development, we ablated central Foxa1 in post-mitotic neurons using the 
Syn1Cre line25. The activity of the Syn1Cre transgene in the STN was confirmed by the loss of endogenous Foxa1 
expression in the STN of adult Foxa1fl/fl; Syn1Cre mice (henceforth called cFoxa1Syn1Cre) (Fig. 3A). Importantly, STN 
formation in cFoxa1Syn1Cre mice was not affected, as Foxp2 and 5-HT2c receptor, two STN-enriched markers, 
were still present in the STN of cFoxa1Syn1Cre mice (Fig. 3A). Similarly, Foxa1eGFP reporter expression remained 
unaltered in the STN of cFoxa1Syn1Cre animals (Fig. 3B).
To assess the spontaneous activity of cFoxa1Syn1Cre mice and their cFoxa1 control littermates, mice were indi-
vidually housed in home cages, where the horizontal movement was automatically tracked for 48 h, using the 
Phenomaster metabolic cage system (T.S.E.). cFoxa1Syn1Cre mice displayed a significant increment in their spon-
taneous locomotor activity compared to the control group. Total horizontal activity as well as traveled distance 
were significantly increased in cFoxa1Syn1Cre mice (Fig. 3C,D). Meanwhile, the metabolic profile of cFoxa1 and 
cFoxa1Syn1Cre mice was comparable. No differences in body weight, energy expenditure, food or water intake were 
detected (Fig. S7A–E).
Next, we compared the locomotor activity of cFoxa1Syn1Cre and cFoxa1 mice after the application of psychoac-
tive substances, applying a within-subject comparison. Lorcaserin is a 5-HT2c receptor agonist and is well known 
for inducing hypolocomotion26. Cocaine, on the other hand, increases motor activity, through the inhibition of 
dopamine reuptake transporters in the striatum27. In line with our earlier findings, the basal activity of cFox-
a1Syn1Cre mice was significantly increased after saline injection (Fig. 3E). Both groups showed the same degree 
of Lorcaserin-induced hypolocomotion, with an ≈ 70% reduction in their activity levels compared to saline 
treatment, but cFoxa1Syn1Cre mice continued to be more active than their cFoxa1 littermates. Cocaine-stimulated 
hyperactivity was observed in mice of both genotypes, but the response of cFoxa1Syn1Cre mice was significantly 
attenuated compared to the control group (Fig. 3E,F). Considering that in cFoxa1Syn1Cre mice Foxa1 is not only 
ablated in the STN, but is also targeted in dopaminergic midbrain neurons, we next wanted to exclude the possi-
bility of a broader motor derailment in cFoxa1Syn1Cre mice. In agreement with the previously reported redundant 
roles of Foxa1/2 in midbrain function we could not detect any significant differences in dopamine tissue contents. 
Moreover the levels of two other catecholamines involved in the central control of activity, norepinephrine and 
epinephrine, were unaltered (Fig. 3G and Fig. S8A,B)28. Furthermore, the levels of characteristic striatal and 
VTA transcripts involved in the modulation of activity were unchanged in cFoxa1Syn1Cre mice, with the excep-
tion of a modest reduction observed in the striatal mRNA levels of the dopamine receptors D1–3 and Ppp1r1b 
(Fig. S8C–E). On the accelerating rotarod, both cFoxa1 and cFoxa1Syn1Cre mice improved their performance with 
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Figure 2. Foxa1 is required at early stages of STN development and its absence is not compensated 
by Foxa2. (A) Combined immunohistochemical and RNA in situ-hybridization analysis of Foxa1eGFP and 
Pitx2 mRNA in the developing hypothalamus of ∆ Foxa1 embryos at E12.5. Arrows indicate the extended 
Foxa1eGFP-positive but Pitx2-negative zone close to the ventricle and the lateral shift in the Pitx2-expressing 
cell population. Shown are representative images. (B) Immunohistochemical analysis of Foxa1eGFP and Pitx2, 
Calb2 and Foxp2 in the developing hypothalamus of ∆ Foxa1embryos at E14.5. Arrows indicate the STN 
cell population in cFoxa1 embryos and its absence in ∆ Foxa1embryos. Shown are representative images. 
(C) Immunohistochemical analysis of Foxa1eGFP and Foxa2 in the STN and midbrain of E14.5 embryos and 
newborn mice (P0). Shown are representative images. STN, subthalamic nucleus. Scale bars represent 100 μm.
www.nature.com/scientificreports/
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the duration of the study (P < 0.001; F = 17.76; df = 2), with no significant effect of the genotype (P = 0.09) 
(Fig. 3H). During the gait analysis on the CatWalk system (Noldus), cFoxa1Syn1Cre mice, like their control litter-
mates, displayed a normal stride pattern, evident by the unaltered regulatory index, step cycle, paw print area 
and stride length (Fig. 3I). These findings are in agreement with a recent study, where impaired neurotrans-
mission in the STN was shown to induce locomotion in the presence of normal motor coordination and gait29. 
Taken together, this suggests that Foxa1 deletion from the STN is at the roots of the observed hyperlocomotion 
Figure 3. Central ablation of Foxa1 induces hyperlocomotion in adult mice. (A,B) Immunohistochemical 
analysis of (A) Foxa1, Htr2c and Foxp2 or (B) Foxa1eGFP on brain sections from adult mice after Syn1Cre-
mediated ablation of Foxa1. Shown are representative images. (C,D) Spontaneous locomotor measures of 
cFoxa1 and cFoxa1Syn1Cre male mice at 20 weeks (n = 16). (C) Total horizontal activity and (D) traveled distance 
were calculated from the number of photobeam interruptions over 48 h. (E,F) (E) Drug-modulated activity of 
24 weeks old cFoxa1 and cFoxa1Syn1Cre male mice after intraperitoneal injection of saline, lorcaserin (7.5 mg/kg) 
or cocaine (10 mg/kg), using a within-subject experimental design. Activity was recorded in 5-min intervals for 
60 min during the dark cycle (n = 8). (F) Normalized to saline treatment for each mouse individually.  
(G) Dopamine tissue content in VTA and striatum of male mice at 24 weeks (n = 8). (H) Crude motor 
coordination assessment on accelerating rotarod, presented as mean of the rounds per min (rpm) reached in three 
trials per day per animal on three consecutive days at 24 weeks (n = 8). (I) Gait analysis on the CatWalk system 
(Noldus) at 26 weeks. All mice had to cross a predefined area for three times and calculations were performed by 
averaging the measurements from all four legs (n = 8). 3V (third ventricle), STN (subthalamic nucleus). Numbers 
are per genotype. Values are expressed as mean ± SEM (C–F), or mean ± s.d. (G–I), *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001; two-tailed Student’s t-test (C–G,I) or 2-way RM ANOVA (H). Scale bars represent 100 μm.
www.nature.com/scientificreports/
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phenotype, whereas midbrain motor programs are not affected by the ablation of Foxa1, probably due to the 
continued presence of Foxa2.
Gene deregulation in Foxa1-deficient STN neurons. Considering the established link between dys-
kinesias and a compromised state of the STN, we next sought to investigate potential changes in the molecular 
characteristics of STN neurons following Foxa1 ablation. To this end we used the Ntsires-Cre line to specifically tar-
get Foxa1 in the STN, presumably around E18.5, based on the Nts in-situ data from the Allen Brain Atlas. When 
comparing the pattern of Foxa1eGFP expression and Cre-dependent tdRFP reporter expression (R26-tdRFPNtsCre), 
Foxa1 and neurotensin expression predominantly overlapped in the STN (Fig. 4A). Because we observed a signif-
icant reduction of Nts transcript levels in the Ntsires-Cre background (Fig. S9A) and considering the large body of 
evidence linking Nts to the modulation of movement, we did not use this line for behavioral studies30,31.
In order to obtain a relatively pure population of STN neurons, we collected Foxa1eGFP- and 
R26-tdRFPNtsCre-labeled, double-positive cells from newborn pups by flow cytometry (Fig. 4B). To identify 
potential perturbations in the STN transcriptome, we performed next generation sequencing (NGS) from STN 
neurons of pups that carried either the Foxa1 wildtype (wtFoxa1NtsCre) or floxed alleles (cFoxa1NtsCre). Analysis 
of the NGS-normalized reads data confirmed the Ntsires-Cre-mediated deletion of Foxa1 in cFoxa1NtsCre pups and 
the complete absence of Foxa2 and Foxa3 from the STN in either genotype (Fig. 4C). Importantly, the isolated 
neurons were rich in STN transcripts while lacking transcripts characteristic of other Foxa1eGFP-expressing neu-
rons, like dopaminergic neurons, underlining the validity of our approach (Fig. 4D). Of note, the glutamater-
gic specification of STN neurons was not affected, as evident by the continued and unaltered expression of the 
vesicular glutamate transporter Vglut2 (Slc17a6) (Fig. 4D and Fig. S9B). Applying gene-set enrichment analysis 
(GSEA), using the curated gene sets from MSigDB C2 (v.5.0), we found that pathways involved in mitochon-
drial function and neurodegeneration were among the most significantly decreased in Foxa1-deficient STN 
neurons (Fig. 4E,F)32. Mitochondrial dysfunction has long been linked to the pathology of neurodegenerative 
diseases, which is reflected in the prominent down-regulation of multiple genes encoding for components of the 
electron transport chain in PD and HD33–38. Accordingly, we found that the majority of down-regulated genes 
associated with oxidative phosphorylation in cFoxa1NtsCre vs wtFoxa1NtsCre neurons was also down-regulated in 
human caudate samples of HD compared to control caudate tissues, further suggesting a degenerate state of 
Foxa1-deficient STN neurons (Table S3)34. Conversely, adenoviral overexpression of Foxa1 in primary neurons 
of newborn mice resulted in a robust up-regulation of a significant fraction of nuclear-encoded transcripts asso-
ciated with mitochondrial biology that were down-regulated in Foxa1-deficient STN neurons (Fig. 4G). Among 
those genes was also the transcriptional coactivator Ppargc1a (Pgc1a), a master regulator of mitochondrial bio-
genesis and itself heavily implicated in neurodegeneration (Fig. 4F,G)36–38. Paralleling the observations made 
in sorted Foxa1-deficient STN neurons, knock-down of Foxa1 by RNA interference in the mouse neuronal cell 
line Neuro-2a (N2a) caused a significant reduction in Ppargc1a transcript levels, including the recently discov-
ered brain-specific Ppargc1a transcripts (Fig. 4H)39,40. Similarly, adenoviral overexpression of Foxa1, but also 
Foxa2, resulted in a dramatic increase in Ppargc1a expression (Fig. 4I). By employing luciferase reporter assays, 
performed in HEK239T cells and using promoter constructs that map to the mouse proximal, alternative and 
brain-specific promoter regions, we could further demonstrate that Foxa1 acts as a transcriptional activator 
of Ppargc1a40. The strongest Foxa1-dependent increase in luciferase activity was measured using a conserved 
genomic DNA sequence flanking and overlapping with brain exon B1 of Ppargc1a, which maps to a CpG island 
and neuron-specific H3K4me3 peak in humans (Fig. 4J)39. By mutagenesis and deletion approaches we identified 
two functional Foxa1 sites, one in the alternative promoter and one in the brain promoter that, when mutated or 
removed, respectively, blunted the Foxa1-induced luciferase activity (Fig. 4J). Finally, we could confirm by chro-
matin immunoprecipitation in Neuro-2a cells that exogenous Foxa1 physically interacts with the chromatin of 
the Ppargc1a locus at brain-specific promoter regions. The enrichment at the proximal and alternative promoter 
regions was markedly lower, probably owing to the neuronal identity of this particular cell line (Fig. 4K).
Loss of Foxa1 induces neurodegeneration in the STN. Considering that Foxa1 deletion from STN 
neurons results in transcriptional changes that are indicative of neurodegenerative events, we hypothesized that 
ultimately a partial loss of STN neurons would ensue. Indeed, when we quantified the number of STN neurons, 
either by stereological counting of NeuN labeled neurons (Fig. 5A), or by determining the neuronal density, using 
NeuN and Foxp2 as neuronal markers in the STN, (Fig. 5B and Fig. S10A–C), we observed a significant loss of 
neurons in the STN of cFoxa1SynCre and cFoxa1NtsCre mice, starting from weaning at 4 weeks of age and at all later 
time points analyzed, including at 8, 20 and 38 weeks of age. To further corroborate these findings, we extended 
our analysis by the inclusion of reporter alleles and quantified NeuN, Foxa1eGFP- and R26-TomatoNtsCre-labeled 
neurons in the STN of wtFoxa1NtsCre and cFoxa1NtsCre mice (Fig. 5C). A Foxa1 dependent neuronal loss was evi-
dent, based on the reduced overall number of neurons, as well as of Foxa1eGFP- or R26-Tomato-labeled STN 
cells (Fig. 5D). Of note, while the number of Foxa1eGFP- and R26-Tomato-co-labeled cells (eGFPposTompos) was 
reduced in cFoxa1NtsCre mice, the number of Foxa1eGFP-positive but R26-Tomato-negative cells (eGFPposTomneg) 
remained constant in both genotypes (Fig. 5D). This observation served as a clear indication that the loss of STN 
neurons is causatively linked to the absence of Foxa1, as only presumptive Foxa1-expressing STN neurons in 
which recombination occurred were affected in their number. Considering that the onset of Syn1Cre and NtsiresCre 
activity occurs still in the prenatal period and that the NGS data obtained from newborns pointed towards a 
degenerative state of Foxa1-deficient STN neurons, we next analyzed the number of STN neurons at P0, but 
found their number to be unaltered (Fig. 5E,F). Taking the reduced STN number at 4 weeks of age into account 
(Fig. S10B,C), the partial loss of STN neurons is likely triggered by neurodegenerative insults in the postnatal 
period prior to weaning. Next, to analyze if STN neurons are only vulnerable to the absence of Foxa1 during the 
early postnatal period, when brain development is still in progress, we tested the ramifications of postnatal Foxa1 
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Figure 4. Transcriptional profiling of Foxa1-deficient STN neurons. (A) Immunohistochemical analysis 
of Foxa1eGFP and R26-tdRFPNtsCre on coronal brain sections of P0 reporter mice. Shown are representative 
images. (B) Collection of STN neurons by flow cytometry for NGS from wtFoxa1NtsCre and cFoxa1NtsCre 
pups. Roughly 1000 STN cells were collected from one newborn for each biological replicate. Shown is a 
representative FACS dot plot. (C) Normalized NGS reads for Foxa1–3. Only Foxa1 reads that are not mapping 
to the Foxa1eGFP transgene were included in the analysis (n = 3). (D) Normalized NGS reads for selected NTS 
and VTA transcripts (n = 3). (E) Top significantly down-regulated pathways in Foxa1-deficient STN neurons, 
www.nature.com/scientificreports/
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ablation on STN integrity. To this end we acutely ablated Foxa1 expression globally at 8 weeks of age, using the 
ubiquitously active tamoxifen-inducible UbcCre/ERT2 line. Four weeks after tamoxifen administration, successful 
Foxa1 deletion was confirmed by real-time PCR in selected organs, including the brain (Fig. S10D). Importantly, 
Foxa1 recombination in the STN was also achieved by this approach, albeit with varying efficiency (Fig. 5G). 
When we counted the number of STN neurons four weeks after the last tamoxifen injection, we could not detect 
any differences between cFoxa1 and cFoxa1UbcCre/ERT2 littermates (Fig. 5H). However, after 20 weeks, the number 
of STN neurons was modestly, yet significantly, reduced in cFoxa1UbcCre/ERT2 mice (Fig. 5H). Interestingly, the 
tamoxifen-induced global ablation of Foxa1 resulted in a yet unreported, significant increase in mortality, thereby 
preventing an extension of the study period beyond the 20 weeks post tamoxifen administration (Fig. S11). Due 
to the widespread tissue deletion of Foxa1 in this model, the underlying physiological and molecular causes for 
this phenotype remain unknown.
In a next step we aimed at investigating the nature of the cell death that causes the partial loss of STN neurons 
in the conditional Foxa1 knock-out models. To this end we crossed cFoxa1Syn1Cre with mice harboring a condi-
tional P53 knock-out allele (cP53). The combined Syn1Cre-mediated deletion of Foxa1 together with the main 
apoptotic driver P53 (cFoxa1; cP53Syn1Cre), (Fig. 5I and Fig. S12A) rescued the loss of STN neurons observed in the 
cFoxa1Syn1Cre mice, suggesting that the degenerative state observed in the sequencing data from Foxa1-deficient 
STN neurons ultimately culminates in apoptotic cell death in a significant fraction of the affected STN cells41.
Finally, we asked the question whether the loss of STN neurons in the conditional Foxa1 knock-out models 
could, at least in part, be attributable to the down-regulation of Ppargc1a. We therefore quantified the number of 
STN neurons in adult Ppargc1a global knock-out mice, where we observed a significant loss of STN neurons in 
addition to the previously reported spongiform lesions (Fig. 5J and Fig. S12B)42.
Reduced firing of Foxa1-deficient STN neurons. Since STN neurons are known to show spontaneous 
activity in the acute slice preparation, we finally assessed the impact of conditional Foxa1 ablation on STN func-
tion by recording spontaneous action potential firing in Foxa1eGFP-positive STN neurons (Fig. 6A)43. We meas-
ured the activity of STN neurons in cFoxa1Syn1Cre and cFoxa1NtsCre mice and their respective cFoxa1 littermates. For 
the Syn1Cre line, STN cells in acute slices prepared from young cFoxa1 control mice displayed spontaneous spike 
discharges at a mean frequency of 7.83 ± 1.86 Hz (n = 10 cells from 3 animals) (Fig. 6B). For the Ntsires-Cre line, 
STN neurons recorded in slices from cFoxa1 control animals showed similar levels of spontaneous activity with 
an average firing rate of 5.76 ± 1.09 Hz (n = 14 cells from 3 animals) (Fig. 6C,D). The firing rate of STN neurons 
in the cFoxa1 control mice from the two different backgrounds was not significantly different (p > 0.3). However, 
when recording STN cells in slices from Foxa1-ablated animals, we found that spontaneous STN cell activity 
levels were markedly reduced in either mouse line, compared to the respective control groups (cFoxa1Syn1Cre; 
p = 0.002, n = 14 cells from 4 animals and cFoxa1NtsCre; p = 0.016, n = 7 cells from 3 animals) (Fig. 6D). Thus, con-
ditional Foxa1 deletion from the STN results in reduced spontaneous activity on the level of individual neurons, 
which likely contributes to an overall compromised STN function.
Discussion
Foxa1 null mice have been reported to perish within a few days after birth, after developing signs of severe growth 
retardation, wasting, progressive starvation and hypoglycemia11,12. Follow-up studies involving the conditional 
deletion of Foxa1 in various peripheral organs, as well as the dopaminergic system have not reproduced the 
drastic phenotype of the global Foxa1 null model, a fact that has been attributed mainly to the extensive overlap 
in tissue distribution and functional redundancy of Foxa1 and Foxa2. Here, we report that in contrast to the 
developing midbrain, where Foxa2 can compensate for the loss of Foxa1, Foxa1 is absolutely essential for the 
formation of the STN13. Analysis of ∆ Foxa1 E14.5 embryos and ∆ Foxa1 newborns revealed the absence of any 
subthalamic specification. Instead we observed an accumulation of Foxa1eGFP neurons in medial positions of the 
developing hypothalamus at P0, which, together with the apparent absence of changes in precursor proliferation, 
survival or cell cycle exit at earlier developmental stages, suggests an inherent failure in the lateral migration and 
thus in the differentiation of STN neurons. Together with the observed defect in mammillary region develop-
ment, this resemblance of phenotypic CNS abnormalities associated with Foxa1 and Pitx2 deficiencies suggests a 
common, yet not redundant role of the two transcription factors in STN and mammillary region formation21,23. 
Mechanistically, the only mild reduction of Pitx2 transcript levels at E12.5 is not in favor of Foxa1 being essential 
determined by pre-ranked GSEA. (F) Heatmap of genes involved in pathways commonly down-regulated in 
STN neurons from cFoxa1NtsCre versus wtFoxa1NtsCre pups, as determined by pre-ranked GSEA (n = 3). (G) RT-
qPCR expression analysis of selected transcripts in primary neurons (DIV4) after overexpression of AdCtrl or 
AdFoxa1 (MOI = 50) (n = 3). Except Tfam, Cycs and Nrf1, all transcripts were significantly down-regulated in 
Foxa1-deficient STN neurons. Shown are data from one representative experiment. (H,I) RT-qPCR analysis 
of Ppargc1a transcript levels after (H) siRNA-mediated knockdown of Foxa1 or (I) adenoviral overexpression 
of Foxa1/2 in N2A cells (n = 4). Shown are data from one representative experiment. (L) Luciferase assays 
performed in HEK293T cells by co-transfecting the indicated promoter constructs with either pcDNA or 
pFoxa1 (n = 3). Shown are data from one representative experiment. Promoter sequence lengths relative to 
the corresponding transcriptional start sites are shown in the method section. (K) Foxa1 ChIP from N2a 
cells transduced with Ad-Ctrl or Ad-Foxa1. Percent recovery of input was calculated by RT-qPCR (n = 3). 
Shown are data from one representative experiment. The binding site positions relative to the corresponding 
transcriptional start sites are shown in the method section. 3V (third ventricle), STN (subthalamic nucleus). 
Numbers are per genotype or condition. All values are expressed as mean ± s.d., ND (not detected), *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001; two-tailed Student’s t-test. Scale bars: 100 μm.
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Figure 5. Foxa1 ablation leads to neurodegeneration in the STN. (A) Stereological counting of NeuN 
labeled STN neurons in cFoxa1, cFoxa1Syn1Cre and cFoxa1NtsCre mice at 20 weeks of age (n = 5–6 mice per 
genotype). (B) Neuronal density (number of neurons per mm2) of STN neurons in cFoxa1, cFoxa1Syn1Cre and 
cFoxa1NtsCre mice at 20 weeks of age (n = 5–6 mice per genotype). (C,D) (C) Immunohistochemical analysis 
and (D) quantification of the neuronal density of individual STN cell populations on sagittal sections from 
wtFoxa1NtsCre and cFoxa1NtsCre mice at 8 weeks (n = 6 mice per genotype). Shown are representative images. 
(E,F) (E) Immunohistochemical analysis and (F) quantification of the neuronal density of individual STN 
cell populations on coronal sections from cFoxa1, cFoxa1Syn1Cre and cFoxa1NtsCre mice at P0 (n = 4–5 mice per 
genotype). Shown are representative images. (G) Immunohistochemical analysis of Foxa1 in the STN at 12 
weeks, 4 weeks after Tx injection. Asterisks demarcate magnified areas. Shown are representative images.  
(H) Neuronal density of STN neurons in cFoxa1UbcCre/ERT2 and cFoxa1 mice 4 weeks (n = 4–5 per genotype) and 
20 weeks (cFoxa1, n = 10; cFoxa1UbcCre/ERT2, n = 15) after Tx injection. (I) Stereological counting of NeuN labeled 
STN neurons in cFoxa1, cP53Syn1Cre, cFoxa1Syn1Cre and cFoxa1;cP53Syn1Cre mice at 16 weeks of age (cFoxa1, n = 6; 
cP53Syn1Cre, n = 3; cFoxa1Syn1Cre, n = 5; cFoxa1; cP53Syn1Cre, n = 4). (J) Stereological counting of NeuN labeled 
STN neurons in WT and Ppargc1a-KO mice at 16 weeks of age (n = 4–5 mice per genotype). STN, subthalamic 
nucleus. Numbers are per genotype. Cell counts are expressed as percentage of the respective control groups. 
All values are expressed as mean ± s.d., NS (not significant), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; ANOVA with 
Dunnett’s post hoc analysis (A,B,F,I), two-tailed Student’s t-test (D,H,J). Scale bars represent 100 μm.
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Figure 6. Spontaneous spiking activity of STN neurons is compromised in the absence of Foxa1.  
(A) Schematic illustration of targeted juxtacellular recordings from Foxa1eGFP-positive STN neurons in 
acute brain slices. Foxa1eGFP-expressing cells were identified by epifluorescence excitation (left panel) and 
subsequently recorded using IR illumination (middle panel). (B,C) Example traces of spontaneous STN-cell 
action potential firing recorded in slices from cFoxa1Syn1Cre and cFoxa1NtsCre mice and their respective control 
littermates. Asterisks denote individual action potentials shown at higher temporal resolution to the right of 
the respective trace. Vertical scale bars are 50 pA. (D) Comparison of STN neuron spontaneous activity levels 
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for Pitx2 expression, and such a model is also not supported by the continued expression of Pitx2 in the medial 
aspects of the developing hypothalamus at E14.5 or P0. During midbrain development Foxa1/2 were shown to 
drive the differentiation of dopaminergic neurons by inducing the expression of and acting cooperatively with 
the transcription factors Lmx1a and Lmx1b14. Interestingly, Lmx1a/b are also expressed in the region of the E12.5 
developing hypothalamus from where the STN neurons originate (www.alleninstitute.org), as well as in the devel-
oped STN44,45. While Lmx1b alone was shown to be dispensable for STN formation, the importance of Lmx1a or 
the combined importance of Lmx1a/b for STN development have not been addressed yet44. We found Lmx1a/b to 
be enriched in Foxa1eGFP-positive vs. Foxa1eGFP-negative neurons, but unlike many other STN markers, they were 
not depleted from Foxa1eGFP neurons of ∆ Foxa1 pups. In addition Lmx1a mRNA was not reduced in the develop-
ing hypothalamus of ∆ Foxa1 embryos at E12.5. It is therefore conceivable that, in analogy to the differentiation 
of dopaminergic neurons, Foxa1 is required in cooperation with Lmx1a/b to initiate the gene expression program 
needed to promote the terminal differentiation STN neurons.
Foxa1/2 expression is required for midbrain development and the maintenance of dopaminergic neuronal 
properties during adulthood. Foxa1/2 mediate this by regulating distinct sets of target genes at the indicated 
stages13–17. Similar to the situation in the midbrain, Foxa1 expression in the STN is not limited to the develop-
mental or postnatal stage but persists throughout adult life. This implies a continuous requirement of Foxa1 for 
the normal functioning of the STN, which in analogy to the midbrain is likely to involve different target genes and 
mechanisms as compared to the role of Foxa1 in the developing STN. Defects in the STN have been associated 
with both hypokinetic and hyperkinetic diseases. Excessive STN activity and hypokinetic symptoms are evident 
in patients suffering from PD, making the STN the most frequent therapeutic target for deep brain stimulation 
in PD46. On the other end of the spectrum, decreased activity of the STN is commonly linked to the hyperkinetic 
symptoms of HD and hemiballism9. In accordance with the current understanding of the basal ganglia circuitry 
and the postulated functional deficit in the STN upon Foxa1 deletion, we observed a hyperlocomotion phenotype 
in cFoxa1Syn1Cre mice. Apart from the overall increase in spontaneous movement, cFoxa1Syn1Cre mice also displayed 
a blunted activity response to cocaine, which is in agreement with a previous study, where STN neurons have been 
ablated by immunotoxin-mediated cell targeting47. In general, lesions or functional impairment of the STN have 
long been known to produce hyperkinetic syndromes in experimental animals and in humans (reviewed in ref. 2).
The link between the observed hyperlocomotion and a potentially impeded STN function was strengthened 
by the finding that adult cFoxa1Syn1Cre mice have an approximately 15–30% reduction in their STN neuron num-
ber. An analogous co-occurrence of increased motor activity and STN degeneration has been observed in mice 
heterozygous for the huntingtin gene, where apoptotic events led to the neurodegenerative loss of approximately 
50% of STN neurons by four months of age48,49. Targeting of Foxa1 in the STN more specifically with the Ntsires-Cre 
line, led to a similar loss of STN neurons as observed in the cFoxa1Syn1Cre model. Importantly, the number of STN 
neurons of cFoxa1Syn1Cre and cFoxa1NtsCre mice at P0 was yet unaltered, but a significant reduction in the STN cell 
number was detected from weaning age onwards. To address whether STN neurons are only susceptible to Foxa1 
loss during the early postnatal period, we acutely induced global Foxa1 deletion in adult mice and observed a 
reduction in the number of STN neurons 20 weeks after tamoxifen injection, suggesting the occurrence of neu-
rodegenerative events.
We could not detect apoptotic markers in actively dying STN cells, like cleaved-caspase-3 or TUNEL -positive 
cells, potentially owing to the transitory nature of these signals and the fact that only very few STN neurons are 
dying at any given time50. However, we were able to prove the occurrence of apoptotic cellular events indirectly, 
by rescuing the STN neuronal loss observed in the cFoxa1Syn1Cre mice through the additional Syn1Cre-mediated 
deletion of the tumor suppressor and main apoptotic driver P53 in cFoxa1;cP53Syn1Cre double knock-out mice41,50.
In line with these observations, RNAseq analysis of Foxa1-deficient STN neurons followed by gene-set enrich-
ment analysis (GSEA) revealed the down-regulation of several genes involved in oxidative phosphorylation, 
indicative of neurodegenerative disorders like PD and HD33. Analysis of published data from human HD and 
control caudate samples revealed that a considerable fraction of these genes was also down-regulated in HD34. 
In this context, earlier studies of post-mortem brain sections of HD patients have revealed the loss of 20–25% of 
STN neurons in addition to the striatal neurodegeneration, which roughly corresponds to the reduction observed 
in the STN of cFoxa1Syn1Cre and cFoxa1NtsCre mice51,52. Intriguingly, we identified Ppargc1a among the deregulated 
targets in Foxa1-deficient STN neurons and could show by a combination of approaches in primary neurons, 
in mouse neuronal N2a cells and in human HEK293T cells that Foxa1 acts as a direct transcriptional activator 
of Ppargc1a expression. Ppargc1a is a master regulator of mitochondrial biogenesis and metabolism that has 
been extensively linked to HD and other neurodegenerative diseases in humans and mice, ablation of which 
causes striatal neurodegeneration and hyperactivity38,42. In addition, genomic traits associated with the Ppargc1a 
genomic locus were shown to modify the age-of-onset of subjects with HD37,39. Ppargc1a knock-out mice display 
a profound hyperactivity that was shown to be associated with striatal neurodegeneration42. Considering the 
reduced number of STN neurons in the Ppargc1a null model, the Ppargc1a deregulation could, at least in part, 
explain the deteriorating state of Foxa1-deficient STN cells.
Finally, we determined how the transcriptional changes induced by the absence of Foxa1 interfere with 
the functional state of individual STN neurons by assessing their intrinsic firing capacity in acute brain slice 
across genotypes. In each mouse line, STN neurons from conditional knock-out animals displayed significantly 
reduced spontaneous action potential firing when compared to the respective Cre-negative controls. Notably, 
there was no difference in STN activity levels between control animals from either mouse line. Data are 
expressed as mean ± SEM, NS (not significant), cFoxa1 (n = 10); cFoxa1Syn1Cre (n = 14, p = 0.0021); cFoxa1 
(n = 14); cFoxa1NtsCre (n = 7, p = 0.0165); cFoxa1 (p = 0.32); cFoxa1Syn1Cre – cFoxa1NtsCre (p = 0.78), two-tailed 
Student’s t-test.
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preparations from cFoxa1Syn1Cre and cFoxa1NtsCre mice. STN neurons from both conditional knock-out models 
displayed a marked reduction in their spontaneous action potential firing rate, suggesting that the functional 
integrity of the Foxa1-deficient STN is not only compromised by the loss of STN neurons, but also by a reduced 
excitatory output at the cellular level. Ideally, ultimate proof for the postulated link between Foxa1 and Ppargc1a 
in the manifestation of the downstream STN neuronal defects would be obtained by a rescue experiment. 
However, it has been shown that such forced expression of exogenous Ppargc1a at non-physiological levels in 
neurons or muscle has deleterious effects on cellular metabolism and viability53,54.
In summary, we propose a model in which deletion of Foxa1 from STN neurons evokes a compromised state 
of the STN, evident by the reduced firing activity of STN neurons and the loss of a significant fraction of STN 
neurons. Based on the current literature, the expected decrease in the firing rate of the main basal ganglia output 
nuclei, the EP and the SNr, and the concomitant disinhibition of the thalamo-cortical connections would ulti-
mately cause the observed hyperkinetic state of Foxa1-deficient cFoxa1Syn1Cre mice.
Material and Methods
Experimental animals. All animal models were kept on a C57BL/6N background. For breedings, 
C57BL/6N male and female mice were purchased from either Janvier or Harlan. Mice were housed in a patho-
gen-free animal facility at the Institute of Molecular Health Sciences at ETH Zurich. Animals were maintained in 
a temperature-controlled room (22 °C), with humidity at 55% on a 12 h light-dark cycle (lights on from 5.30 a.m. 
to 5.30 p.m.). Mice were fed a standard chow laboratory diet and water ad libitum. The age of mice is indicated 
in the figure legends. All animal experiments were approved by the Kantonale Veterinäramt Zürich. Methods 
were carried out in “accordance” with the relevant guidelines of the Kantonale Veterinäramt Zurich. Generation 
of mice deficient for Foxa1 was performed in C57BL/6N embryonic stem cells. The Foxa1eGFP BAC transgenic 
reporter mouse was created by pronucleus injection in C57BL/6N mice. Ntsires-Cre (#017525), Syn1Cre (#003966), 
UbcCre/ERT2 (#008085), R26LSL-Tomato (#007914), cP53 (#008462) and Ppargc1a-KO (#008597) lines were purchased 
from Jackson. R26tdRFP mice were used to sort STN neurons55.
Activity studies. Spontaneous locomotion of adult mice was investigated in metabolic cages on the 
Phenomaster platform (T.S.E.). Metabolic parameters and activity recorded for 48 h after the habituation period 
were used for all calculations. During the study mice had unrestricted access to food and water. All studies were 
conducted at controlled ambient temperature (22 °C) with a constant light and dark phase of 12 h. To study 
drug-modulated locomotion, mice were injected intraperitoneally with either vehicle or drug and single-housed 
in home cages for the duration of the experiment without access to food. 30 min after injection, the horizontal 
activity was recorded for 60 min in 5 min intervals using the Phenomaster platform. Drug studies were performed 
within the second and third hour of the dark cycle. The 5-HT2c receptor agonist Lorcaserin (Selleckchem) was 
diluted in PBS containing 5% of Tween 80 (Sigma) and injected intraperitoneally at 7.5 mg/ kg. Cocaine (Sigma) 
was diluted in saline and administered intraperitoneally at 10 mg/kg. All injections were done at 100 μl per 10 g of 
body weight. Mice were habituated to the handling and the drug administration procedure for 3 days prior to the 
study by intraperitoneal injections of 100 μl PBS once daily. Between the different treatments, mice were granted 
a 7-day drug holiday.
Illumina RNA sequencing. Gene expression analysis of STN neurons was conducted by next generation 
sequencing (NGS). The brains of 3 pups per genotype were dissected and Foxa1eGFP and tdRFPNtsCre double 
positive cells were collected by FACS, yielding on average ~1,000 cells per replicate. The library was generated 
using the Ovation Single Cell RNA-seq System (Nugen) according to the manufactures instructions. The quan-
tity and quality of the libraries were validated using Agilent Tape Station and the libraries were normalized to 
10 nM in Tris-HCl 10 mM, pH 8.5 with 0.1% Tween-20. Diluted libraries were pooled and were further used for 
cluster generation according to the manufacturer’s recommendations using TruSeq SR Cluster Kit v3-cBot-HS 
(Illumina) reagents and sequenced with TruSeq SBS Kit v3-HS reagents (Illumina) on Illumina HiSeq 2000 in the 
high output mode. Single read sequencing at 100 bp was performed. RNA-seq reads were quality checked with 
fastqc. Before mapping, the low-quality ends of the reads were clipped (four bases from the read start and read 
end). Mapping and isoform expression was quantified with the RSEM algorithm (version 1.2.12) with the option 
for estimation of the read start position distribution turned on. Differential gene expression was carried out using 
the R Bioconductor package DESeq2 (v1.8.1).
Stereological cell counting. 40 μm thick, coronal, cryo-sections from 4 to 6 animals per genotype were col-
lected in a series of 4 and 1 series was used for unbiased stereological analysis. For quantification, nickel-enhanced 
DAB-labeled NeuN stainings were performed and the cell numbers were determined according to the optical 
fractionator method with the assistance of the Stereo Investigator v.6.0 software (MicroBrightField)56. A fixed 
counting frame with a width and length of 40 μm and a sampling grid size of 140 × 110 μ m were used. The 
counting frames were placed randomly at the intersections of the grid within the outlined structure of inter-
est by the software. The cells in both hemispheres on sections spanning the planes between Bregma − 2.06 mm 
and − 2.3 mm lateral from the midline, as defined by the Paxinos and Franklin mouse brain atlas, were counted, 
following the unbiased sampling rule56. The estimates of the total number of neurons in the STN obtained by the 
optical fractionator method were normalized to the control group and expressed as percentage. All cell counts 
were performed by an investigator blind to genotype.
Neuronal density analysis. Stainings were performed on 30 μm cryo-sections that were collected in series 
of 3 for mice at 4 weeks and series of 4 for mice at 8 weeks or older. In experiments, where mice carried no 
Foxa1eGFP reporter allele, anti-Htr2c or anti-Calb2 (for paraffin sections) staining was performed to define the 
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borders of the STN. NeuN and Foxp2 stainings were performed to quantify the number of neurons within the 
borders of the STN. Images were acquired within 48 h after staining. Optical sections were acquired at 20x mag-
nification with a Zeiss ApoTome II fluorescence light microscope, Only sagittal sections spanning the planes 
between 1.32 to 1.68 mm lateral from the midline, or coronal sections spanning the planes between Bregma 
− 2.06 mm and − 2.3 mm lateral from the midline, as defined by the Paxinos and Franklin mouse brain atlas, were 
acquired. 4–6 images per mouse were acquired and images were blinded for data analysis. Images were processed 
and analyzed with the Image J software (Fiji package) using the cell counter plugin. STN area was defined by 
Htr2c (or Calb2) or Foxa1eGFP staining and calculated with the Image J software. For each mouse the neuronal 
density (neurons per mm2) was calculated, normalized to the control group and expressed as percentage.
Recording of spontaneous STN activity. Acute parasagittal brain slices containing the STN and neigh-
boring basal ganglia nuclei were prepared as described previously57. In brief, Foxa1Syn1Cre and Foxa1NtsCre mice 
(4–6 weeks, either sex) were anesthetized with ketamine i.p., quickly decapitated and their brains immediately 
removed in ice-cold, oxygenated dissection solution containing (in mM): 120 NaCl, 2.5 KCl, 7 MgCl2, 0.1 CaCl2, 
1.25 NaH2PO4, 26 NaHCO3, 5 HEPES, and 15 glucose, pH 7.4. 400 μm thick sections were cut on a vibrating 
microtome and recovered in oxygenated aCSF containing (in mM): 120 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 1.25 
NaH2PO4, 26 NaHCO3, 5 HEPES, and 15 glucose, pH 7.4 for 1 h at 37 °C before recording. GFP-expressing 
STN-neurons were visualized under a standard microscope (Axio Examiner, Zeiss) equipped with a CCD-camera 
(iXon885, Andor) and a monochromator for epifluorescent illumination (Poly V, FEI Munich). Using IR illumi-
nation, identified GFP-positive cells were targeted for juxtacellular recording of spontaneous action potential 
firing with patch pipettes pulled from borosilicate glass capillaries (3–5 MOhm resistance) filled with inter-
nal solution containing (in mM): 130 K-gluconate, 5 NaCl, 1 EGTA, 5 Mg-ATP, 0.5 Na-GTP, 10 HEPES, pH 
7.35. Recordings were performed at room temperature at a holding potential of − 60 mV in the on-cell con-
figuration of the patch clamp technique using an EPC10 amplifier, controlled by Patchmaster software (both 
HEKA, Lambrecht). Slices were constantly perfused with aCSF containing 20 μM bicuculline at a flow rate of 
approximately 2 ml min−1. Data were sampled at 10 kHz and further analyzed offline using IgorPro (version 5.04, 
WaveMetrics) and Patcher’s Power Tools (http://mpibpc.mpg.de/groups/neher/software). Average spontaneous 
firing frequency was determined from 25–50 s of signal trace and statistical significance was tested with Prism5 
(Graphpad). Data are expressed as mean ± SEM.
Statistical analysis. Statistical analysis was performed by using the statistics software Prism5 (GraphPad). 
Evaluation of data was performed either by two-tailed Students t-test, one-way ANOVA followed by Dunnett’s 
post hoc test, or 2-way RM ANOVA as indicated. P-values are as follows: *P < 0.05, **< 0.01, and ***P < 0.001. 
Data are expressed as mean ± SEM, or mean ± s.d. as indicated.
See Supplementary Information for extended Material and Methods.
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